RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Programmable bacteria synergize with PD-1 blockade to overcome cancer cell-intrinsic immune resistance mechanisms.
Programmable bacteria synergize with PD-1 blockade to overcome cancer cell-intrinsic immune resistance mechanisms.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
干扰素-γ(IFN-γ)是一种强效细胞因子,对免疫治疗应答至关重要,然而全身性递送该细胞因子的常规方法因严重的剂量限制性毒性而受到阻碍。在此,我们工程化改造了一株定植于肿瘤的益生菌,使其在局部释放IFN-γ。单次瘤内注射这些产生IFN-γ的细菌足以驱动全身性肿瘤抗原特异性抗肿瘤免疫,且未观察到毒性。尽管癌细胞利用多种耐药机制逃避免疫应答,细菌来源的IFN-γ通过激活细胞毒性Foxp3- CD4+和CD8+ T细胞,克服了对程序性细胞死亡1(PD-1)阻断的原发性耐药。此外,通过激活自然杀伤(NK)细胞,细菌来源的IFN-γ还克服了对PD-1阻断的获得性耐药机制,特别是IFN-γ信号通路和抗原呈递通路中的功能丧失突变。总体而言,这些结果表明,将产生IFN-γ的细菌与PD-1阻断联合使用,作为克服免疫治疗耐药的局部晚期和转移性疾病的治疗策略具有前景。
Interferon-γ (IFN-γ) is a potent cytokine critical for response to immunotherapy, yet conventional methods to systemically deliver this cytokine have been hindered by severe dose-limiting toxicities.
Here, we engineered a strain of probiotic bacteria that home to tumors and locally release IFN-γ. A single intratumoral injection of these IFN-γ-producing bacteria was sufficient to drive systemic tumor antigen-specific antitumor immunity, without observable toxicity. Although cancer cells use various resistance mechanisms to evade immune responses, bacteria-derived IFN-γ overcame primary resistance to programmed cell death 1 (PD-1) blockade via activation of cytotoxic Foxp3 - CD4 + and CD8 + T cells.
Moreover, by activating natural killer (NK) cells, bacteria-derived IFN-γ also overcame acquired resistance mechanisms to PD-1 blockade, specifically loss-of-function mutations in IFN-γ signaling and antigen presentation pathways. Collectively, these results demonstrate the promise of combining IFN-γ-producing bacteria with PD-1 blockade as a therapeutic strategy for overcoming immunotherapy-resistant, locally advanced, and metastatic disease.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。